Andrea van Elsas, Ph.D.

Interim Chief Scientific Officer; Venture Partner, Third Rock Ventures

Andrea van Elsas is a serial entrepreneur with more than 20 years of experience in biotechnology drug development. In addition to serving as interim chief scientific officer at Abata, he is also a venture partner with Third Rock Ventures and vice president of research at AM-Pharma.

Previously, Andrea served as chief scientific officer at Aduro Biotech following the acquisition of BioNovion, a company he co-founded in 2011. There, he led the company’s global immunotherapy and antibody research programs and oversaw global CMC and technical operations. Before that, he held various positions at Organon (acquired by Schering-Plough and later by Merck), where he directed the company’s immuno-oncology portfolio and led the anti-PD1 program that later became known as pembrolizumab.

Andrea is currently scientific advisory board chair of Lava Therapeutics, scientific advisory board member of InteRNA Technologies and board member of Immunicum AB.

As a postdoctoral researcher, Andrea worked in the lab of 2018 Nobel Laureate Dr. Jim Allison at the University of California, Berkeley and is a co-inventor on the original anti-CTLA-4 patents that formed the basis for the development of ipilimumab, the first checkpoint inhibitor approved in 2011 by the FDA for the treatment of melanoma.

Andrea holds a Ph.D. in immunology and oncology from the University of Leiden.

Back to all posts